Hydrocortisone

Limits on what this shows

• Key negative/null findings: None identified; every source located reports the same direction (glucocorticoid exposure impairing mitochondrial function), all using dexamethasone rather than hydrocortisone.
• At-risk subgroups: Not established for hydrocortisone specifically; the animal/cell-culture literature does not map directly to a human at-risk subgroup.
• Counter-evidence: Cohort test fails for hydrocortisone in every source identified; dexamethasone is a substantially more potent, longer-acting synthetic glucocorticoid, and the magnitude of any hydrocortisone effect is not established by this literature.

Population evidence

"Proanthocyanidins-Mediated Nrf2 Activation Ameliorates Glucocorticoid-Induced Oxidative Stress and Mitochondrial Dysfunction in Osteoblasts" (Chen et al, 2020, PMID 33062149) and "Astaxanthin-mediated Nrf2 activation ameliorates glucocorticoid-induced oxidative stress and mitochondrial dysfunction" (Wang et al, 2024, PMID 38745231) both used dexamethasone to induce the mitochondrial injury being treated. Muscle-atrophy studies (Shen et al, 2019, PMID 30793539; Huang et al, 2018, PMID 30165349) likewise used dexamethasone to induce mitochondrial impairment reversible via SIRT1/PGC-1alpha pathway activation.

Mechanism

Glucocorticoid-receptor signaling suppresses Nrf2 antioxidant-response and PGC-1alpha mitochondrial-biogenesis pathways in osteoblasts and myocytes, reducing mitochondrial membrane integrity and function; all sources found used dexamethasone specifically as the inducing agent.

Counter-evidence held on record

This entry shares its underlying source cluster with Oxidative stress and ATP production below (see Overlap Map); it should not be read as three independent confirmations of the same effect.

Limits on what this shows

• Key negative/null findings: None identified; all sources located are consistent in direction, all using dexamethasone rather than hydrocortisone.
• At-risk subgroups: Not established for hydrocortisone specifically.
• Counter-evidence: Cohort test fails for hydrocortisone in every source; class extrapolation from a more potent synthetic glucocorticoid, capped at yellow.

Population evidence

PMID 33062149 and PMID 38745231 (both dexamethasone-induced oxidative stress in osteoblasts, treated via Nrf2 activation); "Effects of the Glucocorticoid-Mediated Mitochondrial Translocation of Glucocorticoid Receptors on Oxidative Stress and Pyroptosis in BV-2 Microglia" (Dang et al, 2024, PMID 38478195); "Role of PI3K/AKT/MAOA in glucocorticoid-induced oxidative stress and associated premature senescence" (Zhang et al, 2025, PMID 39688282, dexamethasone).

Mechanism

Glucocorticoid receptor activation and its mitochondrial translocation suppress Nrf2-mediated antioxidant response and activate MAOA-linked oxidative pathways, raising reactive oxygen species in the cell types studied; all four sources used dexamethasone.

Counter-evidence held on record

Shares underlying source cluster with Mitochondrial burden and ATP production (see Overlap Map); not independent triple confirmation of the same finding.

Limits on what this shows

• Key negative/null findings: None identified in this review; all three sources point in the same direction (glucocorticoid exposure lowering copper/ceruloplasmin measures).
• At-risk subgroups: Not established for hydrocortisone specifically.
• Counter-evidence: Cohort test fails strictly for hydrocortisone in all three sources (corticosterone in mice, methylprednisolone/dexamethasone in the human study, dexamethasone in the ceruloplasmin study); capped at yellow per Tier C class-extrapolation rules despite the consistent mechanism and direction.

Population evidence

"Chronic Corticosterone Exposure Suppresses Copper Transport through GR-Mediated Intestinal CTR1 Pathway in Mice" (Guo, Chen, Dong, Ni, Zhao, Ma, 2023, PMID 36829476) found corticosterone treatment decreased plasma copper level and plasma ceruloplasmin activity in mice. A human study of synthetic corticosteroids (methylprednisolone, dexamethasone) also found altered plasma copper (Yunice et al, 1981, PMID 7325187), and an animal study examined developmental regulation of hepatic ceruloplasmin by dexamethasone (Fitch, Song, Levenson, 1999, PMID 10320628).

Mechanism

Glucocorticoid receptor activation suppresses expression of the intestinal copper transporter CTR1, directly named in the mouse study, reducing copper absorption; corticosterone is the endogenous rodent glucocorticoid analogous to cortisol/hydrocortisone in humans, and both activate the same glucocorticoid receptor, making this a plausible mechanism for hydrocortisone even though hydrocortisone itself was not the administered compound.

Counter-evidence held on record

The GR-mediated CTR1 mechanism is the most specific, named mechanism found for any trace mineral in this review, but it was demonstrated with corticosterone (the endogenous rodent glucocorticoid), not administered hydrocortisone; treated as strong mechanistic plausibility, not drug-confirmed evidence.

Limits on what this shows

• Key negative/null findings: None identified; no source located this session measures serum iron, ferritin, transferrin saturation, or hepcidin directly in hydrocortisone-treated patients in either direction.
• At-risk subgroups: Not established for hydrocortisone specifically. The review's proposed at-risk population is chronic excess mineralocorticoid-receptor activation generally (primary hyperaldosteronism, Cushing syndrome/disease); by the same logic this would extend most plausibly to patients on prolonged higher-dose or pharmacologic hydrocortisone therapy rather than minimal physiologic replacement.
• Counter-evidence: The primary source is a single-author narrative/perspective review, not a hydrocortisone-administration cohort study, and Tier C under this dossier's rules (narrative review without drug-level stratification); its full abstract and any primary data underlying the transferrin-receptor-1 claim could not be independently verified this session beyond bibliographic and snippet-level detail obtained through PubMed search-listing pages, a Discovery Medicine cross-reference, and OpenAlex metadata, despite genuine multi-channel attempts (PubMed, Europe PMC, Crossref, OpenAlex, Semantic Scholar, ResearchGate, X-MOL, Unpaywall, direct DOI/Elsevier resolution). No study measuring iron parameters in hydrocortisone-treated patients, positive or null, was located at any tier.

Population evidence

"Excess aldosterone and cortisol promote myocardial iron deficiency: A potential pathway to cardiac injury" (Cirovic A, 2026, Journal of Steroid Biochemistry and Molecular Biology, vol 255, PMID 41235980, DOI 10.1016/j.jsbmb.2025.106882) is a single-author narrative review proposing that aldosterone and cortisol, via mineralocorticoid receptor activation, downregulate key iron transporters including transferrin receptor 1, and specifically discusses cortisol's much higher circulating concentration relative to aldosterone as a reason its weaker per-molecule mineralocorticoid-receptor affinity is still physiologically consequential. A companion piece by the same author, "Beyond fibroblast growth factor 23-fibroblast growth factor receptor 4: could aldosterone-driven iron deficiency impact cardiac remodeling in chronic kidney disease?" (Kidney International, 2025, PMID 40846403, DOI 10.1016/j.kint.2025.05.007), develops the aldosterone side of the same mechanism in a chronic-kidney-disease context; it is a brief communication/perspective piece with no retrievable abstract. A hydrocortisone-specific in vitro source was also located, "Effect of hydrocortisone on uptake of iron-59 in incubated rat red cells in vitro" (Clark P, 1961, PMID 13879716), but its abstract and findings could not be retrieved through any channel tried this session (PubMed article page, Europe PMC, Semantic Scholar, and NCBI eutils all returned bot-verification challenges, 429 rate-limit responses, or robots.txt blocks), so it is not used to support this grade and is listed in Sources as identified-but-unverified.

Mechanism

Mineralocorticoid receptor activation is the identical pathway already established at Tier A for hydrocortisone elsewhere in this dossier (label-documented sodium retention and potassium wasting; see Red entries above). The Cirovic review extends this same pathway to transferrin receptor 1 downregulation as a proposed route to myocardial iron deficiency. Hydrocortisone is chemically identical to endogenous cortisol and, at higher or pharmacologic doses, is a direct pharmacologic agonist at the mineralocorticoid receptor the review implicates, though the review's own evidence base concerns endogenous cortisol/aldosterone excess (for example primary hyperaldosteronism, Cushing syndrome, chronic stress) rather than administered hydrocortisone.

Counter-evidence held on record

This is mechanism-level, same-molecule extrapolation (cortisol is chemically identical to hydrocortisone), not hydrocortisone-administration data, and should be read alongside the Oxygen delivery/utilization entry above, which draws on a different endogenous-cortisol-excess mechanism (erythrocytosis) and does not overlap with this one. It is not evidence that iron parameters are altered at typical physiologic-replacement hydrocortisone dosing, and no supplement dose is recommended here (see Safety Review).

Limits on what this shows

• Key negative/null findings: None identified; all sources located are directionally consistent (glucocorticoid exposure disrupting gut microbiome composition/function).
• At-risk subgroups: Not established for hydrocortisone specifically.
• Counter-evidence: Cohort test fails for hydrocortisone in every source located this session; where a specific drug is named it is prednisone, not hydrocortisone, and most studies describe "glucocorticoid" generically without naming the compound in the retrievable material. This is Tier C class extrapolation, capped at yellow, matching the pattern found for the other corticosteroids reviewed in this project.

Population evidence

"Involvement of the Gut Microbiota and Barrier Function in Glucocorticoid-Induced Osteoporosis" (Schepper et al, 2020, PMID 31886921); "Glucocorticoid-induced loss of beneficial gut bacterial extracellular vesicles is associated with the pathogenesis of osteonecrosis" (Chen et al, 2022, PMID 35417243); "Curcumin Ameliorated Glucocorticoid-Induced Osteoporosis While Modulating the Gut Microbiota and Serum Metabolome" (Li et al, 2025, PMID 40139762); "Lactobacillus plantarum attenuates glucocorticoid-induced osteoporosis by altering the composition of rat gut microbiota" (Li et al, 2024, PMID 38264658); a pediatric nephrotic syndrome study linking gut microbiota composition at glucocorticoid therapy onset to relapse risk (Wang et al, 2023, PMID 36815457); and a maternal-exposure study specifically naming prednisone (Ma et al, 2025, PMID 40860437).

Mechanism

Glucocorticoid exposure reduces beneficial gut bacterial taxa and extracellular vesicle output, and impairs intestinal barrier function, which is mechanistically linked to bone loss in these models; this parallels the calcium/bone-turnover finding graded orange above for hydrocortisone specifically, but the microbiome mechanism itself was demonstrated with other glucocorticoids (see Overlap Map).

Counter-evidence held on record

No hydrocortisone-specific gut microbiome study was located despite multi-phrasing searches; graded yellow on consistent, repeated class-level mechanistic evidence only.

Limits on what this shows

• Key negative/null findings: None identified; all four sources are consistent in direction and mechanism.
• At-risk subgroups: Not established for hydrocortisone specifically; steroid myopathy (a related clinical outcome, not the same as this ATP entry) is separately listed on the hydrocortisone label as an adverse reaction (see PK Basis and Hard Rule 2 distinction).
• Counter-evidence: Cohort test fails for hydrocortisone in every source; dexamethasone is a substantially more potent, longer-acting glucocorticoid than hydrocortisone, so magnitude at hydrocortisone-equivalent exposure is not established.

Population evidence

"Chinese leek-derived extracellular vesicles ameliorate sarcopenia by regulating mitochondrial biogenesis" (Qi et al, 2025, PMID 41261435) reported that the intervention "restored ATP production" and reduced ROS levels in a dexamethasone-induced muscle-impairment model. "Qigu capsule alleviates dexamethasone-induced muscle dysfunction through mitochondrial biogenesis" (Jinyu et al, 2025, PMID 40810219) examined ATP content and mitochondrial respiratory chain function directly. "Myricanol rescues dexamethasone-induced muscle dysfunction via a sirtuin 1-dependent mechanism" (Shen et al, 2019, PMID 30793539) and "Dihydromyricetin Attenuates Dexamethasone-Induced Muscle Atrophy by Improving Mitochondrial Function" (Huang et al, 2018, PMID 30165349) both used dexamethasone as the inducing agent for the muscle/ATP deficit being treated.

Mechanism

Glucocorticoid-receptor-driven suppression of SIRT1/PGC-1alpha signaling reduces mitochondrial biogenesis and respiratory chain capacity in skeletal muscle, lowering cellular ATP output; consistently demonstrated with dexamethasone, not hydrocortisone.

Counter-evidence held on record

Shares underlying source cluster with Mitochondrial burden and Oxidative stress (see Overlap Map). This is distinct from the label's "steroid myopathy" adverse-reaction entry, which is a clinical outcome, not a direct ATP measurement (Hard Rule 2).

Limits on what this shows

• Key negative/null findings: None identified; no source located in this review suggests hydrocortisone or cortisol excess causes anemia or impaired oxygen delivery.
• At-risk subgroups: Not a depletion risk group; the "at-risk" framing does not apply in the usual sense. Patients on prolonged higher-dose/pharmacologic hydrocortisone therapy are the population where this reverse-direction erythropoietic effect would be most plausible.
• Counter-evidence: This is endogenous hypercortisolism data, not a study of administered hydrocortisone; the cohort test is satisfied for the molecule (cortisol = hydrocortisone) but not for drug administration, so the finding is graded yellow rather than higher.

Population evidence

"Patients with hypercortisolemic Cushing disease possess a distinct class of hematopoietic progenitor cells leading to erythrocytosis" (Varricchio, Geer, Martelli, et al, 2023, Haematologica, PMID 35861015) found that patients with active Cushing disease exhibited erythrocytosis associated with a unique CD34+ hematopoietic progenitor cell population.

Mechanism

Sustained glucocorticoid-receptor activation stimulates expansion of erythroid progenitor populations, increasing red cell mass; because hydrocortisone is chemically identical to endogenous cortisol, this endogenous-excess (Cushing disease) human data is directly mechanistically relevant to prolonged higher-dose hydrocortisone therapy, even though hydrocortisone was not itself the administered agent in this study (the excess cortisol was endogenous, from a pituitary or adrenal source).

Counter-evidence held on record

This is a reverse-direction, excess-mechanism finding (erythrocytosis, not anemia). It must never be read as evidence that hydrocortisone improves oxygen delivery in ordinary use, and it is not evidence for any supplement or intervention (Hard Rule 5 framing). Per Hard Rule 2, this is also distinct from the label's own intended anti-inflammatory/immunosuppressive mechanism and is not filed as such.